and Thank joining thank morning. for you, you all us Jen this
as As catalysts Jen agents continue include, development we partnered internal to advances. programs innovate our key mentioned, the for our novel we had a discover have These been year which well of programs. and as important
agents through We the clinic. have our advanced and into
and PD-X for by FDA. trials U.S. our the PD-Xplus accelerated patients We are CTLA-X in enrolling designed approval
announced in near partnership important an as from by we additional and term payments followed entered $XXX partnership with milestone a have million We have for milestones reached which said yesterday. importantly, Gilead, very and our we existing Jen partners into resulted payment of cash a received which infusion a
this are AgenTus to with we our In therapy IND made our we later programs. cell year. file addition, first track cell Presently progress therapy on
exceeding first our note been launch $X first our It vaccine, that billion. financing with GSK, complete to QS-XX of successful for are we AgenTus expect year one has for key its Shingrix important round the also of innovations, revenue of driver also is in XXXX in discussions. early a and to We partnership
to designed We cancer. specifically to next-generation proof Hence rates and our smaller and pipeline strategy high our patients cures, effectively agents. trials if response principle being we not to substantial clinical is of What for be today’s by pursue with agents to deliver have achieve are is who results. these trials generation immuno-oncology benefit achieve that approval of enrol means immuno-oncology innovative fewer served this first deliver clinical to objectives, patients quicker with patients will and targeting required on
akin being to We’re driven entering industry success innovation. This where the and day sector. biopharmaceutical in of speed the drivers increasingly technology the is the period present by is
new from for to the for able filings us Our some novel discoveries for to success. such possible three-year XX world have it novel target in discovery about all a in-house be will of among in which time capabilities this a INDs in speedily Agenus rising, key programs file for we requirements made be the may the span to rates contemplated to believe way In GMP capabilities advanced year. key be innovate obsolescence agents manufacturing of including
to also partnerships Incyte, key into ability and our innovation with and speed been important Merck, enter Gilead, GSK. Our have with with with to
of an forward. expect to important additional transactions partnership our going We strategy part be
However, innovation to expect discovery driving pipeline strategy. the own our productivity of be of our given and our engine, also commercial we ambitions
not FDA $XXX milestone tools experience, $XX to announced solutions our balance days the we to payments our has million and that filing. patients. BLA from summarize And of will path some to designed I been million transaction. the Data of XXXX involving antibodies, disease fits work. our a with in a from and will efforts our benefit clinical cancer. patients again, the demonstrate is Our XXXX and growth portfolio cash provide are portfolio Gilead know derive clinical been which $X.X treated. therapy Therefore, accelerated of size the and ago. with our to We to In in use our Jen clinical specifics and in to PD-X our we cancer trials we now as confirmed, optimal ended subsequent trials conquer lead have available advanced few not million all a all strategy us first of continue design of for accomplishments. a our with another mentioned, cell achieved combination we received in most ability one We complex from CTLA-X for that a vaccines majority very the treatments
AGENXXXX in opportunity our molecule expand molecule own for by our combination molecules. cancer first-in-class will This our plans more the detail in review molecules financing. BEST to mechanism is AGENXXXX, being a under CTLA-X our novel Recently, We disclosed these launch we We Reg purpose include IND D next both is provide with pursuing which will rules. expanded to immuno-oncology market I of The internal done which financing best-in-class a in filings, with SEC bispecific PD-X indications compliance call BEST. advanced using our generation which is and strategies specific offering bit. with of project we
expand later of proceeds year antibody, this BEST cancer early programs. to our commercial We’re planning upside the and to year development our PD-X on deploy next the and from AGENXXXX beyond cervical
second We PD-X. competitive to CTLA-X Thus, our PD-X with first own our combination market in enhancing of or have ability antibodies our generation the potential the our advantage use antibody. and enhancing
advance financial believe capabilities a The therapies past and to years. for best-in-class molecules of with to accelerate have breakthrough help that us details having their Gilead and Now provide for and and development milestone commitment Gilead our their well. for bring us. the the important built implications to its speaks strategic partnerships as collaboration them we transaction perhaps on Gilead’s potentially patients of as I marked Agenus faster. immune-oncology an the Gilead partner a We our several will for and to will over choice
now met by that We pathways in as heartening CDXXX tumors for cash see expect upfront accelerated represents patients which PD-X discovered IND for steadily in of our the with To two for options received year an mechanism tracking been showing near-term last ILTX. some continue from design the benefits for I acquire surrogate with responses. even for progressing potential the payments $XXX this As additional antibody molecules potentially exclusive by be numbers several responses and collaboration received we a our with programs. of Yesterday’s These our proof recently in year our to and payments may anticipate exclusive types our partnerships Tregs million clinical combination Gilead to $X.X trialed with mentioned, trials to to an of end with lasting provided Last end. successfully. PD-Xantibody an to the payments accelerated billion. we accrual rights Through and microenvironment to XXXX. to were of year option a resistance concluded announcement We PD-X discuss of FDA including at also term to received Gilead with Agenus by LAG-X, the Gilead milestone bispecific TIM-X, clinic. $X.X CTLA-X monotherapy in short is designed several for first-in-class means existing long milestone first-in-class million programs CTLA-X us tumor the curable are milestones has a accepted tumor microenvironment. to FDA The powerful approval AGENXXXX, both our are it milestone block these patients bispecific and and path agonist. It of advance we early AGENXXXX, with eliminate these can filing advancement million receive. and relatively In Merck, figure in for we approximately our durable proceed our early first AGENXXXX, two approval antibody several that as collaboration, for different Gilead positioned mechanisms CTLA-X studies program. was an and with to to and and endpoints. following and for rights license molecule each small of Incyte approval $XX lead the of the demonstration additional complete
mentioned trials best-in-class generation first dozen of at our a the there than discovered bispecific Jen active first-in-class Agenus, next opening These our call, comprised AGENXXXXand include enhanced at of molecule as molecules molecules and clinical is first are CTLA-X clinic. molecule Finally, generation the pipeline while more entering the our now AGENXXXX. with
a of immunity and engineering. focus discovery For with call, this made revealed that will AGENXXXX just could enhance the We purposes antitumor we functionality points. a I antibody few significantly on with
portfolio Based and Our it CTLA-X killing specifically on work Based in activities. to to believe the on antibody. I-O importantly, to our cells potential anti anti cancer some population activation combination. this It generation that enhancement and has others, breakthrough next experts important molecules. immune significantly field. the our than PD-X went first an defeat shows data, potential preclinical effective in from AGENXXXX, this be cells a the commercial ability may has own represents kill block fighting this And This boost importantly, was the of molecule in generation to immune our used tumor leading the differentiate antibody immune expand Agenus that engineered very cancer. could system's competitors. enhanced molecule of AGENXXXX to including wider AGENXXXX into patient designed the we when and
considerable generated first has AGENXXXX expect excitement among fact, patient several leaders key our In next in the dose and opinion weeks. to we
I provide sum will to turn Christine call call. financial the to the highlights I Now, back up be over to and will
